Overview

Magnetic Resonance Imaging (MRI) in Predicting Response to Sunitinib Malate in Patients With Locally Advanced or Metastatic Kidney Cancer

Status:
Completed

Trial end date:
2018-11-01

Target enrollment:

Participant gender:

Summary

Rationale: Diagnostic procedures, such as MRI, may help doctors predict a patient's response to treatment and help plan the best treatment. Purpose: This clinical trial is studying MRI in predicting response to sunitinib malate in patients with locally advanced or metastatic kidney cancer.

Details

Lead Sponsor:

Abramson Cancer Center of the University of Pennsylvania
University of Pennsylvania

Collaborator:

National Cancer Institute (NCI)

Treatments:

Sunitinib